MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression

Abstract MEK inhibitors (MEKi) have limited efficacy in KRAS mutant lung adenocarcinoma (LUAD) patients, and this is attributed to both intrinsic and adaptive mechanisms of drug resistance. While many studies have focused on the former, there remains a dearth of data regarding acquired resistance to...

Full description

Bibliographic Details
Main Authors: Dylan A. Farnsworth, Yusuke Inoue, Fraser D. Johnson, Georgia de Rappard-Yuswack, Daniel Lu, Rocky Shi, Lok In Josephine Ma, Marissa S. Mattar, Romel Somwar, Marc Ladanyi, Arun M. Unni, William W. Lockwood
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-022-00328-x

Internet

https://doi.org/10.1038/s41698-022-00328-x

Similar Items